Mesoblast's Ryoncil Gains FDA Approval for Pediatric Use Mesoblast Limited has received FDA approval for its flagship treatment, Ryoncil, targeting steroid-refractory acute graft-versus-host disease in children. The product is expected to be available in U.S. clinics soon, with a pricing strategy set at $194,000 per infusion. This marks a significant milestone for the company.123